SEPOY.net
No Result
View All Result
Tuesday, June 17, 2025
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
  • Home
  • News
  • Business
  • Health
  • Tech
  • Lifestyle
  • Economy
  • Crypto
  • Travel
No Result
View All Result
SEPOY.NET
No Result
View All Result
Home Health

Study reveals a novel therapeutic strategy to overcome tumor-induced immunosuppression

Nicholas by Nicholas
August 30, 2022
in Health
0

A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumor-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in Frontiers in Immunology.

READ ALSO

Estrogen-responsive cells found to heighten gut pain in females

First patient treated in international clinical trial for rare muscle-weakness disease

“Immunotherapy is one of the most promising areas in oncology,” notes senior author Lucio Miele, MD, PhD, Assistant Dean for Translational Research at LSU Health New Orleans School of Medicine, who is also a cancer researcher. “Our immune systems are capable of destroying cancer cells, and several approved and experimental drugs stimulate cancer immunity. But cancers fight back, producing substances that weaken immune cells.”

The immune system cells that kill cancer cells are called CD8 T-cells. To be effective, CD8 T-cells need a protein made by the NOTCH1 gene.

“We had already described how adenosine, an immune-suppressive substance released by tumor cells, causes the breakdown of NOTCH1, weakening T-cells,” says Dr. Miele.

Using a proteomics strategy, the LSU Health New Orleans research team led by postdoctoral researcher Giulia Monticone, PhD, determined what causes the breakdown of NOTCH1 in T-cells. It is an enzyme called CBL-B. Collaborating with a Massachusetts biotech firm that is developing CBL-B inhibitors, the scientists were able to show that their experimental inhibitors do protect NOTCH1 from breaking down in CD8 T-cells and make them far more effective in killing breast and colorectal cancer cells.

“When added to existing immunotherapeutics, these CBL-B inhibitors greatly increased their potency,” Dr. Miele adds. “This new strategy could expand the efficacy of cancer immunotherapy by making patients’ T-cells able to evade the immune-suppressive defenses of tumors.”

Co-authors also included Drs. Deniz Ucar, Fokhrul Hossain, Salome Ibba, Hamid Boulares, Zhi Huang, and Samarpan Majumder at LSU Health New Orleans; Drs. Fred Csibi, David Ciccone, Silvana Leit, and Christine Loh from Nimbus Therapeutics; Dr. Ameya Champhekar from the University of California; Jermaine Austin from the University of Virginia; Dr. Nick Carpino from Stony Brook University; Dr. Keli Xu from the University of Mississippi Medical Center; and Dr. Barbara Osborne from the University of Massachusetts Amherst.

The research was supported by a grant from the National Cancer Institute.

Source:

Louisiana State University Health Sciences Center

Journal reference:

10.3389/fimmu.2022.987298

Tags: CancerCellDrugsEnzymeimmunityImmunologyImmunosuppressionImmunotherapyMedicineOncologyResearchT-CellTumor

Related Posts

Estrogen-responsive cells found to heighten gut pain in females
Health

Estrogen-responsive cells found to heighten gut pain in females

June 17, 2025
First patient treated in international clinical trial for rare muscle-weakness disease
Health

First patient treated in international clinical trial for rare muscle-weakness disease

June 16, 2025
Paternal mental health found to impact child development
Health

Paternal mental health found to impact child development

June 16, 2025
Two existing medications work effectively together in treating alcohol use disorder
Health

Two existing medications work effectively together in treating alcohol use disorder

June 16, 2025
FDA approval of pembrolizumab marks major shift in head and neck cancer treatment
Health

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

June 16, 2025
Health care employment rebounds after the pandemic but staffing gaps remain
Health

Health care employment rebounds after the pandemic but staffing gaps remain

June 16, 2025
Next Post

The night in Ukraine: Kyiv goes on the offensive in the south

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About

Sepoy.net is a perfect place for people who want daily updates on news related to business, technology, entertainment, health, cryptocurrency etc.

Contact: hello@sepoy.net

Major Categories

News

Business

Tech

Economy

 

Recent Posts

  • Courtroom Sa internet Baccarat Sa america Pinakadakilang mga Internet site At booi casino online Aplikasyon
  • Baccarat Sa web Maglaro ng Ganap booi mobile na libre at Isang tunay na kita Agarang Pagsusugal
  • Casino Bonus inte med insättningskrav & omsättningskrav Testa avgiftsfri

Pages

  • About Us
  • Contact Us
  • Disclaimer
  • DMCA
  • Home
  • Privacy Policy

© 2023 Sepoy.net

No Result
View All Result
  • Home
  • Business
  • News
  • Health
  • Tech
  • Science
  • Lifestyle
  • Travel

© 2023 Sepoy.net